Overall, these results suggest that one of the early events in the skin of psoriasis patients after adalimumab treatment is decreased attraction of immune cells by first downregulation of chemokines and then their receptors (e.g. IL8 after 4 days and IL8RB after 14 days). This evidence concerns the gene CXCR2 and psoriasis.